Floatz logo

Moxetumomab Pasudotox

Leukemia, Prolymphocytic Leukemia, Small

MedImmune LLCantibody_drug_conjugatePhase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Leukemia, Prolymphocytic Leukemia, Small cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Fludarabine
Center for International Blood and Marrow Transplant Research
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
FILGRASTIM
Center for International Blood and Marrow Transplant Research
Phase 2BB
TACROLIMUS
Center for International Blood and Marrow Transplant Research
Phase 2BB

View all 50 →

Same molecule, other indications

Moxetumomab Pasudotox is also rated in:

acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →